U.S. stock movement | Merck (MRK.US) rises over 4% Winrevair achieves success in new mid-term trial for lung indication.

Zh tng cijng APP hu xn, zhu'r, m sh dng (MRK.US) zhng y 4%, bo 96.97 miyun. Gi gngs zhu'r xunb, q hud FDA pzhn de fi dng mi goy (PH) liof Winrevair zi fi dng mi goy hunzh zhng ddole zhyo mbio, fi dng mi goy sh y zhng y fi b gngun xuyn xuy dinjn wi tzhng de jbng. According to the Zhitong Finance APP, on Tuesday, Merck (MRK.US) rose more than 4%, reaching $96.97. The company announced on Tuesday that its FDA-approved pulmonary arterial hypertension (PH) therapy, Winrevair, has achieved its primary goal in patients with pulmonary arterial hypertension, a disease characterized by high blood pressure in the blood vessels supplying the lungs.